Cargando…

Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys

Preclinical studies of HIV-1 vaccine candidates have typically shown post-infection virologic control, but protection against acquisition of infection has previously only been reported against neutralization-sensitive virus challenges(1–3). Here we demonstrate vaccine protection against acquisition...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barouch, Dan H., Liu, Jinyan, Li, Hualin, Maxfield, Lori F., Abbink, Peter, Lynch, Diana M., Iampietro, M. Justin, SanMiguel, Adam, Seaman, Michael S., Ferrari, Guido, Forthal, Donald N., Ourmanov, Ilnour, Hirsch, Vanessa M., Carville, Angela, Mansfield, Keith G., Stablein, Donald, Pau, Maria G., Schuitemaker, Hanneke, Sadoff, Jerald C., Billings, Erik M., Rao, Mangala, Robb, Merlin L., Kim, Jerome H., Marovich, Mary A., Goudsmit, Jaap, Michael, Nelson L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3271177/ https://www.ncbi.nlm.nih.gov/pubmed/22217938 http://dx.doi.org/10.1038/nature10766

Ejemplares similares

Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys
por: Liu, Jinyan, et al.
Publicado: (2008)

Association of Progressive CD4(+) T Cell Decline in SIV Infection with the Induction of Autoreactive Antibodies
por: Kuwata, Takeo, et al.
Publicado: (2009)

Accelerated heterologous prime-boost adenovirus vector-based SIV vaccine in neonatal rhesus monkeys
por: Liu, J, et al.
Publicado: (2012)

Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV-Infected Rhesus Monkeys
por: Borducchi, Erica N., et al.
Publicado: (2016)

Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV(mac)239
por: Jia, Bin, et al.
Publicado: (2009)

Origin of rebound virus in chronically SIV-infected Rhesus monkeys following treatment discontinuation
por: Liu, Po-Ting, et al.
Publicado: (2020)

Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques
por: Ventura, John D., et al.
Publicado: (2022)

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
por: Barouch, Dan H., et al.
Publicado: (2021)

2775. Safety and Immunogenicity of a Seasonal Influenza Vaccine and Ad26.RSV.preF Vaccine With and Without Co-Administration: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study in Adults Aged ≥ 60 Years
por: Comeaux, Christy, et al.
Publicado: (2019)

Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19
por: Barouch, Dan H., et al.
Publicado: (2021)

ADCC Develops Over Time during Persistent Infection with Live-Attenuated SIV and Is Associated with Complete Protection against SIV(mac)251 Challenge
por: Alpert, Michael D., et al.
Publicado: (2012)

OA05-06 LB. First-in-human Phase 1 safety and immunigenicity of an adenovirus serotype 26 HIV-1 vaccine vector
por: Baden, LR, et al.
Publicado: (2009)

Rapid Loss of CD4 T Cells by Pyroptosis during Acute SIV Infection in Rhesus Macaques
por: He, Xuan, et al.
Publicado: (2022)

Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors
por: Iampietro, M. Justin, et al.
Publicado: (2018)

Adenovirus vectors from various serotypes induce distinct cytokine profiles
por: Teigler, JE, et al.
Publicado: (2012)

Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )
por: Le Gars, Mathieu, et al.
Publicado: (2022)

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
por: Sadoff, Jerald, et al.
Publicado: (2022)

The Role of Innate APOBEC3G and Adaptive AID Immune Responses in HLA-HIV/SIV Immunized SHIV Infected Macaques
por: Wang, Yufei, et al.
Publicado: (2012)

Rapid Seeding of the Viral Reservoir Prior to SIV Viremia in Rhesus Monkeys
por: Whitney, James B., et al.
Publicado: (2014)

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
por: Sadoff, Jerald, et al.
Publicado: (2021)

Accessories to SIV Control: T Cell Vaccination Shows Potential
por: Robb, Merlin L., et al.
Publicado: (2017)

TRIM5 alpha Drives SIVsmm Evolution in Rhesus Macaques
por: Wu, Fan, et al.
Publicado: (2013)

Models of SIV rebound after treatment interruption that involve multiple reactivation events
por: van Dorp, Christiaan H., et al.
Publicado: (2020)

Early immune events during acute HIV infection
por: Slike, BM, et al.
Publicado: (2012)

Therapeutic vaccination of SIV-infected, ART-treated infant rhesus macaques using Ad48/MVA in combination with TLR-7 stimulation
por: Bricker, Katherine M., et al.
Publicado: (2020)

Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys
por: Kang, Zi Han, et al.
Publicado: (2018)

Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques
por: Cadena, Anthony M., et al.
Publicado: (2021)

Adaptive immune responses to SARS-CoV-2()
por: Forthal, Donald
Publicado: (2021)

Epitope specificity appears to be an important determinant of in vivo killing ability of simian immunodeficiency virus (SIV)-specific CD8+ T Cells
por: Pozzi, L, et al.
Publicado: (2012)

Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge
por: Cox, Freek, et al.
Publicado: (2018)

LB7. Ad26.COV2.S-Elicted Neutralizing Activities Against SARS-CoV-2 Variants of Concern in Phase 1/2a and Phase 3 Clinical Trials
por: Le Gars, Mathieu, et al.
Publicado: (2021)

First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine
por: Walsh, SR, et al.
Publicado: (2012)

Induction of a virus-specific effector–memory CD4(+) T cell response by attenuated SIV infection
por: Gauduin, Marie-Claire, et al.
Publicado: (2006)

Mosaic HIV-1 Vaccines Expand the Breadth and Depth of Cellular Immune Responses in Rhesus Monkeys
por: Barouch, Dan H., et al.
Publicado: (2010)

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer
por: Sadoff, Jerald, et al.
Publicado: (2021)

Delineation and Modulation of the Natural Killer Cell Transcriptome in Rhesus Macaques During ZIKV and SIV Infections
por: Aid, Malika, et al.
Publicado: (2020)

Evidence for Env-V2 sieve effect in breakthrough SIV (MAC251) infections in rhesus monkeys vaccinated with Ad26/MVA and MVA/Ad26 constructs
por: Sina, S, et al.
Publicado: (2012)

SIV Vpx Is Essential for Macrophage Infection but Not for Development of AIDS
por: Westmoreland, Susan V., et al.
Publicado: (2014)

GCM-SIV1.5: Optimal Tradeoff between GCM-SIV1 and GCM-SIV2
por: Zhang, Ping
Publicado: (2023)

Development of replication-competent adenovirus based vaccine vectors
por: Abbink, P, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ssus4iuvud6s00g0jvlehgti0s